The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / A New Treatment for Axial Spondyloarthritis?

A New Treatment for Axial Spondyloarthritis?

June 17, 2019 • By Mary Beth Nierengarten

  • Tweet
  • Email
Print-Friendly Version / Save PDF

If approved by the U.S. Food and Drug Administration (FDA), difficult-to-treat patients with axial spondyloarthritis who fail or are intolerant to standard treatment with tumor necrosis factor inhibitors (TNFi) may have a new treatment option.

You Might Also Like
  • Certolizumab Pegol in Nonradiographic Axial Spondyloarthritis
  • Ixekizumab Improves Outcomes of Ankylosing Spondylitis
  • Management of Psoriatic Arthritis, Treatment of Axial Spondyloarthritis Addressed at EULAR 2016
Explore This Issue
June 2019
Also By This Author
  • Update on ACR’s Rheumatology-Specific APM

That new option is a high-affinity monoclonal antibody, called ixekizumab, which selectively targets an area linked to the immunopathology of axial spondyloarthritis—specifically, the interleukin (IL) 17 axis. Prior studies have shown the efficacy of IL-17 inhibition in patients with axial spondyloarthritis. Secukinumab is the first agent in this class to show efficacy in treating patients with this condition.1-3 Most of the secukinumab trials enrolled patients who were exclusively or predominantly disease-modifying anti-rheumatic drug (DMARD) naive. Lacking, however, are data evaluating the efficacy of IL-17 inhibition specifically in patients who fail to respond adequately to, or are intolerant of, TNF inhibitors.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

A new study looked at the efficacy and safety of ixekizumab in this setting.

“Ankylosing spondylitis is a chronic and debilitating disease, and I have a large number of patients who have failed TNF inhibitors,” says lead author of the study Atul Deodhar, MD, a professor of medicine and the medical director of the Rheuma­tology Clinics in the Division of Arthritis & Rheumatic Diseases at the Oregon Health & Science University in Portland. “There’s a need for more options specifically for difficult-to-treat patient populations. This research provides valuable insights into the potential for ixekizumab to become a new treatment option for patients with ankylosing spondylitis,” he says.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Focus on Difficult-to-Treat Patients

Dr. Deodhar

Dr. Deodhar

Called the COAST-W trial, the phase 3 randomized controlled trial enrolled 316 patients with active radiographic axial ankylosing spondylitis who had an inadequate response to or were intolerant to one of two TNF inhibitors. Most patients in the study were white men (80%), and most (n=315) had been treated with a prior TNF inhibitor. Of these, 205 (65.1%) had an inadequate response to one TNF inhibitor, 78 (24.8%) had inadequate response to two TNF inhibitors and 32 (10.2%) were intolerant to TNF inhibitors.

Patients were randomized for 16 weeks to one of three treatment groups: placebo (n=114), 80 mg of ixekizumab subcutaneously every two weeks (IXEQ2W) (n=98), or 80 mg of ixekizumab subcutaneously every four weeks (IXEQ4W) (n=114). The starting dose in each treatment group was either 80 mg or 160 mg.

The primary outcome of the study was an Assessment in SpondyloArthritis Inter­national Society 40% response (ASAS40), representing at least a 40% improvement in signs and symptoms of disease.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

As shown in Table 1 (see above), significantly more patients treated at either dose of ixekizumab achieved the study’s primary outcome compared to those treated with placebo.

According to the study authors, a significant response by patients in both treatment groups was observed as early as the first week of treatment.

“This is the first dedicated study to measure the effect of biologic therapy in this patient population, including spinal inflammation, by using magnetic resonance imaging [MRI],” says Dr. Deodhar, who emphasized the importance of using MRI to assess spinal inflammation.

Assessing spinal MRI and systemic inflammation was a secondary outcome of the study. Using the mean change in MRI spine Spondyloarthritis Research Consortium of Canada (SPARCC) scores at baseline and serum mean change from baseline C-reactive protein (CRP) levels at 16 weeks to measure spinal and systemic inflammation, the study found patients treated with ixekizumab had a statistically significant reduction in inflammation seen on spinal MRI compared to placebo (–11.0 in the IXEQ2W group, –9.6 in the IXEQ4W group and –1.5 in the placebo group).

“Patients treated with ixekizumab experienced a statistically significant reduction in inflammation seen on spinal MRI compared to placebo,” he says, emphasizing that the measure used to assess spinal inflammation on MRI is “an objective measure that adds to the subjective measures of symptom relief.”

Pages: 1 2 3 | Single Page

Filed Under: Conditions, Spondyloarthritis Tagged With: axial spondyloarthritis (SpA), high-affinity monoclonal antibody, ixekizumab, tumor necrosis factor (TNF) inhibitorsIssue: June 2019

You Might Also Like:
  • Certolizumab Pegol in Nonradiographic Axial Spondyloarthritis
  • Ixekizumab Improves Outcomes of Ankylosing Spondylitis
  • Management of Psoriatic Arthritis, Treatment of Axial Spondyloarthritis Addressed at EULAR 2016
  • Subcutaneous Golimumab in Active Non-Radiographic Axial Spondyloarthritis

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)